Senti Biosciences Holdings Inc SNTI

$2.02 -0.77 (-27.60%)

Valuation

Market cap
2,710,000
Revenue TTM
$20,000
Net income TTM
$-61,440,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-307,200.00%
Debt to equity
0.00

Trading

Volume
28,038
Avg volume
137,402
Day's range
$2.02 – $2.59
Shares out
31,145,000
Stochastic %K
10%
Beta
2.31
Analysts
Moderate Buy
Price target
$6.00

Price

Company profile

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications wit...

Show more

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 239 2030
Website
https://www.sentibio.com
Address
2 Corporate Drive, First Floor, South San Francisco, United States

Latest news

Stocktwits

Marketmoverjoe Nov 20, 12:16 PM
$SNTI POS company. wtf? tired of these companies existing off the hard earned dollars of investors. Shame on you
0 replies
GridironGainz Nov 19, 10:11 PM 0 replies
TwongStocks Nov 19, 9:19 PM
Today's reverse split results. $SCNI 1 for 4 Previous close $0.3673, $1.4692 split-adjusted Today's high $1.73 Today's close $1.5542 🟢Up 5.79% $SNTI 1 for 33 Previous close $0.087, $2.871 split-adjusted Today's high $3.02 Today's close $2.79 🔴Down 2.82% $YFOR 1 for 50 Previous close $0.022, $1.10 split-adjusted Today's high $1.36 Today's close $1.13 🟢Up 2.73%
0 replies
GridironGainz Nov 19, 8:57 PM 0 replies
TwongStocks Nov 19, 12:59 PM
$SCNI $SNTI $YFOR All three with reverse splits today, full details in the quoted post. Trading resumes at 9:00am ET with the RS in effect.
0 replies
giancachimi Nov 19, 7:11 AM 0 replies
PSM_EmpowerTrading Nov 19, 3:56 AM
🌅 Watchlist part 2 ✅ $INHD low 4 support, above 4.5, potential to 5/6 ✅ $SNTI 1/33 rs, new price ~2.8 ✅ $SCNI 1/4 rs, new price ~1.5 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $RFL $PMVP still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D
0 replies
PSM_EmpowerTrading Nov 19, 3:56 AM
🌅 Watchlist part 1 ✅ $INHD low 4 support, above 4.5, potential to 5/6 ✅ $SPRC low .30 support, above .5, potential to .7/.8 ✅ $GMM 1.50 support, above 1.80, potential to 2/2.5 ✅ $YFOR 1/50 rs, new price ~1.1 ✅ $SNTI 1/33 rs, new price ~2.8 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D
0 replies